Collaborative Arrangements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization					$ 1,020	$ 1,163
Sales	$ 15,035		$ 14,593		29,522	30,494
Operating Segments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales	14,913		14,223		29,126	29,812
Operating Segments | Pharmaceutical
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales	13,457		12,756		26,179	26,863
Lynparza
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization						250
Lynparza | Other Noncurrent Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets	1,700				1,700
Lenvima
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization					72
Lenvima | Operating Segments | Pharmaceutical
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales	242		231		474	459
Lenvima | Other Noncurrent Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets	756				756
Verquvo | Other Intangible Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets	55				55
Adempas | Operating Segments | Pharmaceutical
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales	65		63		125	124
Adempas | Other Intangible Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets	586				586
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales	47		$ 33		90	86
AstraZeneca | Sales-Based Milestones | Lynparza
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable contingent payments				$ 600
Liabilities				$ 600
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales-based milestone payments						400
Potential future sales-based milestone payments	2,100				2,100
Capitalized milestone payment	245	$ 105				175	$ 250
Potential future regulatory milestone payments	850				850
Eisai | Sales-Based Milestones | Lenvima
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable contingent payments		125
Liabilities		$ 125
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales-based milestone payments						600
Potential future sales-based milestone payments	$ 2,400				$ 2,400
Capitalized milestone payment						25	$ 50
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales-based milestone payments						400
Bristol Myers Squibb Company | Licensing Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate, deduction					0.50
Bristol Myers Squibb Company | Licensing Agreements | Sales-Based Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent proceeds collaborative arrangement					$ 80
Bristol Myers Squibb Company | Licensing Agreements | Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators						$ 20
Bristol Myers Squibb Company | Licensing Agreements | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate					20.00%
Bristol Myers Squibb Company | Licensing Agreements | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate					24.00%